Advertisement
News
Subscribe to MDT Magazine News

58% of Physicians Support FDA Move to Pull Breast Cancer Indication from Avastin

February 4, 2011 7:35 am | by Bio-Medicine.Org | Comments

CAMBRIDGE, Mass., Feb. 4, 2011 /- Sermo ( http://www.sermo.com ), the world's largest online community for physicians, announced the publication of a free Sermo Report about how physicians are reacting to the FDA decision to rescind the indication for Avastin (bevacizumab) in the...

TOPICS:

Photocure Announces Positive Allumeraâ„¢ Trial Results for Delivering Significant Skin Appearance Improvements

February 4, 2011 7:35 am | by Bio-Medicine.Org | Comments

OSLO, Norway, Feb. 4, 2011 /- Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance....

TOPICS:

Earnings Preview: Humana reports 4Q earnings

February 4, 2011 6:45 am | by The Associated Press | Comments

Health insurer Humana Inc. reports fourth-quarter financial results on Monday before the market opens.WHAT TO WATCH FOR: Humana said late last year that its forecast for 2011 earnings would slip by about a dollar per share from the prior year due mainly to less favorable trends for its crucial...

Advertisement

R.I. council awards $1.4M to eight projects

February 4, 2011 6:36 am | by Mass High Tech: The Journal of New England Technology | Comments

The Rhode Island Science and Technology Advisory Council (STAC) has singled out eight research projects and 23 scientists from 13 institutions for a total of $1.4 million in grants.

Avecia Biotechnology acquired by Japanese firm

February 4, 2011 6:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Avecia Biotechnology Inc., a DNA- and RNA-based therapeutics firm in Milford, has been acquired by Japanese materials manufacturer Nitto Denko Corp.

Federal Register: Industry Exchange Workshop on Food and Drug Administration Drug and Device Requirements; Public Workshop

February 4, 2011 5:30 am | by U.S. Food & Drug Administration | Comments

This 2-day public workshop is intended to provide information about FDA drug and device regulation to the regulated industry.

TOPICS:

MEDfx to Harmonize the Direct Project With CONNECT

February 4, 2011 4:35 am | by Bio-Medicine.Org | Comments

WARWICK, R.I., Feb. 4, 2011 /- MEDfx Corporation today announced a Direct Project pilot that demonstrates health information exchange among providers using a combination of the standards and protocols supported by the Direct Project and the FHA CONNECT Gateway. MEDfx is participating in,...

TOPICS:

FDA Approves Makenaâ„¢, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm ...

February 4, 2011 4:33 am | by Bio-Medicine.Org | Comments

ST. LOUIS, Feb. 4, 2011 /- K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a specialty pharmaceutical company, announced today that it has been informed by Hologic, Inc. that the U.S. Food and Drug Administration (FDA) granted approval for Makena™ (hydroxyprogesterone...

TOPICS:
Advertisement

FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women

February 4, 2011 4:33 am | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., Feb. 4, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery before 37 weeks of pregnancy, in pregnant women with a history of at least one...

TOPICS:

FDA Approves Hologic's Makenaâ„¢ (Formerly Referred to as Gestivaâ„¢) Pharmaceutical

February 4, 2011 4:33 am | by Bio-Medicine.Org | Comments

BEDFORD, Mass., Feb. 4, 2011 /- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the...

TOPICS:

Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders

February 4, 2011 4:33 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., Feb. 4, 2011 /- Novo Nordisk announced today the availability of Coags Uncomplicated – the first mobile application (app) to assist in the diagnosis of bleeding disorders – created in partnership with Craig Kessler, MD, Professor of Medicine and Pathology and...

TOPICS:

WebMD to Present at the UBS 21st Annual Global Healthcare Services Conference

February 4, 2011 4:33 am | by Bio-Medicine.Org | Comments

NEW YORK, Feb. 4, 2011 /- WebMD Health Corp. (Nasdaq: WBMD ) today announced that Wayne Gattinella, President and CEO, will deliver a presentation at the UBS 21st Annual Global Healthcare Services Conference on Tuesday, February 8, 2011 at 12:00 p.m. ET. Investors, analysts and the...

TOPICS:

Aetna's 4Q profit jumps 30 percent(2)

February 4, 2011 1:46 am | by The Associated Press | Comments

Health insurer Aetna says its fourth-quarter net income rose 30 percent as it benefited from higher pricing and a slowdown in health care use that also has helped its competitors.The Hartford, Conn., insurer said Friday it earned $215.6 million, or 53 cents per share, in the three months that...

Aetna's 4Q profit jumps 30 percent

February 4, 2011 1:46 am | Comments

Health insurer Aetna says its fourth-quarter net income rose 30 percent as it benefited from higher pricing and a slowdown in health care use that also has helped its competitors.The Hartford, Conn., insurer said Friday it earned $215.6 million, or 53 cents per share, in the three months that...

FDA Grants Orphan Drug Designation to Bayer's Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors

February 4, 2011 12:34 am | by Bio-Medicine.Org | Comments

WAYNE, N.J., Feb. 4, 2011 /- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading